• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Merck

EMD Serono wins FDA nod for redesigned pen injector

November 13, 2017 By Sarah Faulkner

EMD Serono

Merck KGaA‘s biopharma biz, EMD Serono, said today that it won FDA approval for a redesigned version of its Gonal-f RFF Redi-ject pen injector. The device, which was first approved in 2013, is designed to inject follitropin alfra to induce ovulation and pregnancy in oligo-anovulatory women. The newly-designed pen was evaluated in a simulated-use study involving […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Wall Street Beat, Women's Health Tagged With: emdserono, Merck

Startup aims to disrupt asthma, COPD space with digital inhaler

November 8, 2017 By Sarah Faulkner

Pneuma Respiratory device

Formed just two years ago, pharma startup Pneuma Respiratory is developing a digital inhaler that it touts as the first of its kind. The company is looking to bring its technology to the more than 40 million people who suffer from asthma or chronic obstructive pulmonary disease in the U.S. They’re stepping into a highly […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: cree, generalelectric, GlaxoSmithKline plc, Merck, Pfizer Inc., pneumarespiratory, Propeller Health

Merck raises full-year guidance despite mixed Q3

October 27, 2017 By Sarah Faulkner

Merck

Shares in Merck (NYSE:MRK) slipped in pre-market activity today after the pharmaceutical company beat earnings estimates but missed sales expectations on Wall Street with its third quarter results. The Kenilworth, N.J.-based company posted a loss of -$51 million, or -2¢ per share, on sales of $10.33 billion for the 3 months ended Sept. 30. This quarter’s […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Merck

Sanofi files patent infringement suit against Mylan over insulin pen

October 25, 2017 By Sarah Faulkner

Sanofi logo

Sanofi (NYSE:SNY) filed a patent infringement suit against Mylan (NSDQ:MYL) yesterday in the U.S. District Court of New Jersey, alleging that the EpiPen-maker infringed upon 18 patents covering Sanofi’s Lantus insulin glargine injection and SoloStar pen. The suit was triggered by a notice from Mylan in mid-September, Sanofi said. Mylan told the insulin-maker that it had […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: Merck, Mylan, Sanofi-Aventis

LifeMine Therapeutics combines AI, drug discovery & microbes with $55m launch

September 18, 2017 By Sarah Faulkner

microbe

Backed by the likes of Google and Merck (NYSE:MRK), Cambridge, Mass.-based LifeMine Therapeutics launched today by closing a $55 million Series A round. The company calls itself the first to “massively scale the genomic discovery of powerful new drugs from eukaryotic microbes”. LifeMine plans to use artificial intelligence to hunt down drugs hidden within the DNA […]

Filed Under: Discovery, Featured, Funding Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Google, lifeminetherapeutics, Merck

Merck leads $11m round for Antidote’s trial-matching tech

September 7, 2017 By Sarah Faulkner

antidote

Antidote Technologies said today that it inked an $11 million funding round to advance its clinical trial matching technologies. The round was led by Merck’s Global Health Innovation Fund. Existing investors Smedvig Capital and Octopus Ventures participated in the round, which is contingent upon obtaining certain regulatory clearances and is expected to close later this […]

Filed Under: Clinical Trials, Featured, Funding Roundup, Pharmaceuticals, Wall Street Beat Tagged With: antidotetechnologies, Merck

Fresenius closes Merck biosimilar biz purchase

September 1, 2017 By Sarah Faulkner

Fresenius Kabi

Fresenius Kabi said today that it closed its acquisition of Merck KGaA’s biosimilars unit. The company paid €156 million at closing ($185.7 million USD) and could pay up to €500 million ($595.2 million USD) in milestone payments, which are contingent upon meeting certain drug development targets. Previously, Fresenius announced it would pay €170 million upfront ($202.4 million […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Fresenius, Merck

Federal judge dismisses faulty birth control suit against Merck

August 25, 2017 By Sarah Faulkner

Merck

A Maine federal judge tossed out a woman’s lawsuit against Merck (NYSE:MRK), after she claimed that the company’s Nexplanon birth control implant allegedly failed to keep her from becoming pregnant. Kayla Doherty filed the suit in April 2015, seeking damages related to the costs of raising a child as a single mother and costs related to […]

Filed Under: Drug-Device Combinations, Featured, Implants, Legal News, Pharmaceuticals, Wall Street Beat, Women's Health Tagged With: Merck

Update: Industry panels disintegrate in wake of Trump remarks

August 16, 2017 By Sarah Faulkner

capitol hill

A pair of industry panels convened by President Donald Trump disintegrated today in the wake of his latest comments on the racist violence in Charlottesville. After Merck (NYSE:MRK) CEO Kenneth Frazier announced on Monday that he planned to leave Trump’s manufacturing advisory panel, a wave of executives followed in his path. Today, reversing from a statement […]

Filed Under: Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Capitol Hill, johnsonandjohnson, Medtronic, Merck

Merck CEO Frazier leaves Trump council

August 14, 2017 By Sarah Faulkner

Merck

Merck (NYSE:MRK) announced today that chief executive Kenneth Frazier plans to resign from President Donald Trump’s American Manufacturing Council, citing the president’s mild-mannered response to a white nationalist rally in Virginia on Saturday. The “Unite The Right” gathering turned deadly when a car mowed down a group of counter-protesters, killing at least one person and injuring […]

Filed Under: Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Capitol Hill, Merck

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS